Literature DB >> 19216863

[Syndrome differentiation and treatment of Taiyang disease in Shanghan Lun].

Xue Yang1, Wen-Bo Peng, Xiao-Qiang Yue.   

Abstract

OBJECTIVE: To explore the laws in syndrome differentiation of Taiyang disease and the prescriptions and herbs used in its treatment in Shanghan Lun (Treatise on Febrile Diseases).
METHODS: The occurrence rates of main syndromes of Taiyang disease, and the usage frequency of the prescriptions and herbs in its treatment were calculated, and the laws in syndrome differentiation and herbal medication were analyzed by hierarchical clustering analysis.
RESULTS: Fever and aversion to cold were found to be the main symptoms of Taiyang disease and usually accompanied with headache, absent sweating, neck stiff, floating and tight pulse, and body ache. The accompanying or aggravated symptoms could be classified into lung system syndrome with the manifestations of sweating and asthma, spleen-deficiency syndrome with the manifestations of gastric fullness and diarrhea, stomach syndrome with vomit and constipation. Guizhi decoction was the main prescription used in the treatment of Taiyang disease. Mahuang (Herba Ephedrae) matching Xingren (Semen Armeniacae), Dahuang (Radix et Rhizoma Rhei) matching Mangxiao (Natrii Sulfas), Baizhu (Rhizoma Atractylodes Macrocephalae) matching Fuling (Poria), Fuzi (Radix Aconiti Lateralis) matching Ganjiang (Rhizoma Zingiberis), Chaihu (Radix Bupleuri) matching Huangqin (Radix Scutellariae), Banxia (Rhizoma Pinelliae), and Renshen (Radix Ginseng) as the main compatibilities were used in treating lung diseases, stomach diseases, spleen-deficiency diseases, kidney-deficiency diseases and Shaoyang diseases respectively.
CONCLUSION: Exterior syndrome, as a common syndrome in Taiyang disease, is usually treated with Guizhi decoction. The change in syndromes from upper-energizer to lower-energizer in exterior disease can be found from the change of symptoms and the use of herbs. And the development from defending stage to qi stage in exterior disease can be found in the use of prescriptions in Shanghan Lun.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19216863     DOI: 10.3736/jcim20090215

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  6 in total

1.  Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats.

Authors:  Yinghong Tang; Mengkai Zheng; Yu-Lin Chen; Jianzhen Chen; Yu He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

2.  Antiviral effects of Yinhuapinggan granule against influenza virus infection in the ICR mice model.

Authors:  Xue-qian Peng; Hui-fen Zhou; Yu-yan Zhang; Jie-hong Yang; Hai-tong Wan; Yu He
Journal:  J Nat Med       Date:  2015-10-06       Impact factor: 3.192

3.  Ma Huang Tang Suppresses the Production and Expression of Inflammatory Chemokines via Downregulating STAT1 Phosphorylation in HaCaT Keratinocytes.

Authors:  Hye-Sun Lim; Chang-Seob Seo; Seong-Eun Jin; Sae-Rom Yoo; Mee-Young Lee; Hyeun-Kyoo Shin; Soo-Jin Jeong
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-26       Impact factor: 2.629

4.  Chaihu Guizhi Ganjiang Decoction Ameliorates Pancreatic Fibrosis via JNK/mTOR Signaling Pathway.

Authors:  Lihua Cui; Caixia Li; Ye Shang; Dihua Li; Yuzhen Zhuo; Lei Yang; Naiqiang Cui; Yuhong Li; Shukun Zhang
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

5.  The Profiling and Identification of the Absorbed Constituents and Metabolites of Guizhi Decoction in Rat Plasma and Urine by Rapid Resolution Liquid Chromatography Combined with Quadrupole-Time-of-Flight Mass Spectrometry.

Authors:  Hongjun Xiang; Lishi Zhang; Jiannan Song; Bin Fan; Yinglan Nie; Dong Bai; Haimin Lei
Journal:  Int J Mol Sci       Date:  2016-09-12       Impact factor: 5.923

6.  New Therapeutic Insight into the Effect of Ma Huang Tang on Blood Pressure and Renal Dysfunction in the L-NAME-Induced Hypertension.

Authors:  Mi Hyeon Hong; Hye Yoom Kim; Youn Jae Jang; Se Won Na; Byung Hyuk Han; Jung Joo Yoon; Chang Seob Seo; Ho Sub Lee; Yun Jung Lee; Dae Gill Kang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.